Get App
Download App Scanner
Scan to Download
Advertisement

Torrent Pharma Shares In Focus After Q4 Results; Nirmal Bang Sees Limited Upside At Current Valuations — Check Revised Target Price

While the JB Pharma acquisition strengthens Torrent's India franchise and medium-term growth visibility, current valuations largely factor in the near-term earnings and synergy benefits, says Nirmal Bang

Torrent Pharma Shares In Focus After Q4 Results; Nirmal Bang Sees Limited Upside At Current Valuations — Check Revised Target Price
Torrent Pharma's Q4 FY26 consolidated results came in ahead of the brokerage's estimates, largely aided by consolidation of JB Pharma from 21-Jan-26; however, the standalone/base business performance remained broadly in line with estimates.
(Photo: NDTV Profit/ AI generated image)
STOCKS IN THIS STORY
Torrent Pharmaceuticals Ltd.
--

NDTV Profit's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer NDTV Profit's subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Nirmal Bang Report

Domestic brokerage firm Nirmal Bang has maintained Hold rating on Torrent Pharmaceuticals Ltd. with a target price of Rs 4,898, valuing the company at 24x FY28E EV/Ebitda, implying ~10% premium to its five-year average multiple.

While the JB Pharma acquisition strengthens Torrent's India franchise and medium-term growth visibility, current valuations largely factor in the near-term earnings and synergy benefits

Torrent Pharma's Q4 FY26 consolidated results came in ahead of the brokerage's estimates, largely aided by consolidation of JB Pharma from 21-Jan-26; however, the standalone/base business performance remained broadly in line with estimates.

Excluding JB Pharma, Torrent delivered 16% YoY revenue growth with Ebitda margin sustained at 32.7%, supported by continued strong traction across key branded markets.

India business outperformed the IPM led by chronic therapies, Curatio scale-up and early success in semaglutide launches, while Brazil maintained healthy momentum driven by new launches and pricing actions.

The US business continued to recover aided by recent launches and improved offtake from existing products.

Click on the attachment to read the full report:

Nirmal Bang Torrent Pharma Q4 Results Review.pdf
VIEW DOCUMENT

ALSO READ: Samvardhana Motherson Q4 Review: Motilal Oswal Ups Target Price On Long-Term Growth Outlook — Check Upside

DISCLAIMER

This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.

To continue reading this story
You must be an existing Premium User

Newsletters

Update Email
to get newsletters straight to your inbox
⚠️ Add your Email ID to receive Newsletters
Note: You will be signed up automatically after adding email

News for You

Set as Trusted Source
on Google Search
Add NDTV Profit As Google Preferred Source
Loading PDF...